BioMark Diagnostics

BioMark Diagnostics ROIC

The Return on Invested Capital (ROIC) of BioMark Diagnostics (BUX.CN) as of Oct 29, 2026 is -446.20 %. In the previous year, Return on Invested Capital (ROIC) was -101.35 % — a change of 340.27% (lower).

ROIC

-446.20 %

YoY

340.27%

Last updated:

Return on Invested Capital (ROIC) of BioMark Diagnostics is 2026 -446.20 % . Return on Invested Capital (ROIC) of BioMark Diagnostics was 2025 -101.35 % . It decreases by 340.27% lower compared to the previous year.

The BioMark Diagnostics ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2019
44.75 CAD
Jan 1, 2020
276.75 CAD
Jan 1, 2021
-3,584.45 CAD
Jan 1, 2022
-1,271.03 CAD
Jan 1, 2023
262.01 CAD
Jan 1, 2024
918.25 CAD
Jan 1, 2025
-101.35 CAD
Jan 1, 2026
-446.20 CAD
The BioMark Diagnostics ROIC history
YEARROICYoY
-446.20 %+340.27%
-101.35 %-111.04%
918.25 %+250.46%
262.01 %-120.61%
-1,271.03 %-64.54%
-3,584.45 %-1,395.20%
276.75 %+518.47%
44.75 %-44.56%
80.71 %+20.15%
67.17 %-73.46%
253.14 %-113.03%
-1,943.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioMark Diagnostics Stock analysis

What does BioMark Diagnostics do? BioMark Diagnostics, Inc. generates revenue by developing and commercializing cancer diagnostic solutions designed to detect, monitor, and assess treatment for cancer. The company leverages a molecular diagnostics technology platform that combines metabolomics and machine learning algorithms to enable physicians to detect carcinomas in pre-symptomatic stages. This approach aims to improve cancer prognosis and allows for measuring response to treatment as well as serial monitoring of cancer survivors. The firm focuses on cancers that are difficult to detect and treat by utilizing its liquid biopsy assay to detect Spermidine/spermine N-acetyltransferase 1, an enzyme with elevated levels in numerous cancers. Additionally, the company has developed a high-powered liquid biopsy metabolic panel assay which is instrumental for the early-stage diagnosis of lung cancer. These products serve the medical market by providing advanced tools for early detection and ongoing patient management. BioMark Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMark Diagnostics stock

Return on Invested Capital (ROIC) of BioMark Diagnostics is -446.20 % in 2026.

Return on Invested Capital (ROIC) of BioMark Diagnostics changed from -101.35 % to -446.20 %, representing a 340.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) BioMark Diagnostics since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s BioMark Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — BioMark Diagnostics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — BioMark Diagnostics